182 related articles for article (PubMed ID: 36448244)
1. Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
Mandoli GE; Pastore MC; Giannoni A; Benfari G; Dini FL; Rosa G; Pugliese NR; Taddei C; Correale M; Brunetti ND; Mazzeo P; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; De Carli G; Degiovanni A; Patti G; Santoro C; Moderato L; Cicoira M; Canepa M; Malagoli A; Emdin M; Cameli M
ESC Heart Fail; 2023 Apr; 10(2):846-857. PubMed ID: 36448244
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
De Vecchis R; Paccone A; Di Maio M
Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
[TBL] [Abstract][Full Text] [Related]
4. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
[TBL] [Abstract][Full Text] [Related]
5. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
8. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
9. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
[TBL] [Abstract][Full Text] [Related]
10. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
[TBL] [Abstract][Full Text] [Related]
11. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
[TBL] [Abstract][Full Text] [Related]
12. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
[TBL] [Abstract][Full Text] [Related]
13. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
[TBL] [Abstract][Full Text] [Related]
14. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
Naser N; Kulić M; Jatić Z
Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
[TBL] [Abstract][Full Text] [Related]
15. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
Fröb EJ; Sindermann JR; Reinecke H; Tuleta I
Adv Clin Exp Med; 2022 May; 31(5):475-487. PubMed ID: 35092651
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
[TBL] [Abstract][Full Text] [Related]
20. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
